Cite
MLA Citation
Alfonso Yubero et al.. “2022-RA-466-ESGO Long-term responders (LTR) to rucaparib in recurrent ovarian cancer: a sub-group analysis from the rucaparib access (RAP) program in Spain by GEICO.” International journal of gynecological cancer, vol. 32, n.d., p. A238. http://access.bl.uk/ark:/81055/vdc_100168339637.0x000038